LIVN - Success of team-selling model has Baird seeing more upside in healthcare equipment maker

After a post-earnings rally yesterday, one healthcare equipment company reached up and touched $90/share, for just a minute - and "stocks that go to $90 tend to go to $100," or so the aphorism goes, Baird notes. But $100 is its new price target for LivaNova (LIVN), which closed Wednesday up 4.2% after hitting a new two-year high intraday following its Q1 print. "Sure, electives broadly are recovering and there's an end of service backlog still to convert," analyst Mike Polark writes. "But ... tone and vibes seemed quite upbeat, especially anecdotes about recent successes of team-based selling model focused on the level 4 centers including first implants at longtime holdouts." Epilepsy was still its standout area, the firm notes, with revenues expected to rise 15-20% (in constant currency) for 2021. The higher-touch, team-based approach targeting level 3 and 4 epilepsy centers is bearing fruit. By the end of the

For further details see:

Success of team-selling model has Baird seeing more upside in healthcare equipment maker